Riskpilot← Back to searchSign inGet full accessSwedish Perfusion Holding AB
ABActiveOrg 5568769466Dalagatan 47 1407Activities of holding companies · NACE 6421Est. 20110 employees
Revenue 2025
SEK 0
EBITDA margin
—
-591% vs 2024
Equity ratio
70.8%
Financial strength
Net profit 2025
SEK 12K
+7% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -6K | -591% |
| Net profit | SEK 12K | +7% |
| Total assets | SEK 3M | +0% |
| Equity | SEK 2,1M | +1% |
| Employees | 0 | — |
Legal name
Swedish Perfusion Holding AB
Org number
5568769466
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
19 december 2011
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska förvalta fastigheter, själv eller genom dotterbolag samt bedriva annan därmed förenlig verksamhet.
Address
Dalagatan 47 1407
Phone
+46705890543
Email
swed.perf@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 | 3 | 5 | 5 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 | −1 | −3 | −1 | −6 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −1 | −1 | −3 | −1 | −6 |
| Net financials | 2 001 | 4 | 14 | 13 | 21 |
| Profit before tax | 2 000 | 3 | 12 | 14 | 15 |
| Tax | −0 | −1 | −2 | −3 | −3 |
| Net profit | 2 000 | 2 | 9 | 11 | 12 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 916 | 2 918 | 2 930 | 2 946 | 2 956 |
| Equity | 2 057 | 2 060 | 2 069 | 2 080 | 2 092 |
| Long-term debt | 858 | 858 | 858 | 858 | 858 |
| Short-term debt | 0 | 1 | 3 | 5 | 3 |
| Total debt | 858 | 859 | 861 | 863 | 861 |
EBITDA margin
-648500.0%
This company
15.8%
Market median
-4104530% vs market
20212025
Equity ratio
70.8%
This company
38.2%
Market median
+85% vs market
20212025
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20212025
Net profit margin
1171500.0%
This company
8.1%
Market median
+14462863% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.41×
This company
0.62×
Market median
+34% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Swedish Perfusion Holding AB 
Swedish Perfusion AktiebolagBoard members of Swedish Perfusion Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Michael Kenneth Wussow | Board of Directors | 0 companies |
| Tim Marcus Sebastian Wussow | Deputy Board Member | 0 companies |
| Per Mathias Niklas Wussow | Chairman | 0 companies |